Clinical Trial Detail

NCT ID NCT03904108
Title Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors ROGER S MD KERESZTES
Indications

lung non-small cell carcinoma

Therapies

Ramucirumab

Age Groups: adult senior

Additional content available in CKB BOOST